Fresenius Medical Care reports third quarter 2026 performance partially offsetting headwinds and narrowing full year outlook
Key Highlights
- ➤Q3 revenue EUR 4,937 million, up 1% reported and down 1% constant currency
- ➤Q3 reported operating income EUR 384 million, down 19% year-on-year
- ➤Q3 reported net income EUR 160 million, down 42% on China strategy costs
- ➤5008X CAREsystem reached 348 U.S. clinics and 1.3 million treatments
- ➤FY 2026 operating-income outlook narrowed to flat to negative mid-single-digit growth
Expert Statements
Shervin J. Korangy, Chief Executive Officer and Chair of the Management Board of Fresenius Medical Care
“Three weeks into my role as CEO, I am energized by the opportunities ahead. As a global leader in kidney care, Fresenius Medical Care combines exceptional capabilities with unparalleled reach. Following the structural changes of recent years, many parts of our business are still at an early stage of development. This creates a compelling opportunity to deliver transformational improvements in performance, not simply the incremental gains typically associated with more mature businesses. We are muted in our assessment of performance and endeavor to improve the current trajectory over time”
Martin Fischer, Chief Financial Officer of Fresenius Medical Care
“Fresenius Medical Care delivered a quarter of broadly stable revenue and resilient earnings development, as continued underlying performance improvements counter the expected negative effects from TDAPA regulations and increased inflation headwinds. Care Delivery further increased operating income(2), driven by continued underlying operating income(2) improvement of 21% excluding the negative TDAPA effects. The U.S. rollout of our innovative 5008X CAREsystem is progressing on plan, now available in 348 U.S. clinics, having performed 1.3 million treatments. The ongoing experience with the HvHDF modality in our clinics is exciting and clinical observations are consistently tracking very well compared with real-world data outside the U.S., which show to significantly improve patient outcomes.”
Shervin J. Korangy, Chief Executive Officer and Chair of the Management Board of Fresenius Medical Care
“Based on the operating income development in the first nine months and the anticipated headwinds in the fourth quarter we narrowed our outlook for 2026 to the lower half of our outlook range.”
Fresenius Medical Care reports third quarter 2026 performance partially offsetting headwinds and narrowing full year outlook PR Newswire
* Stable organic revenue(1) development driven by growth in Care Delivery and Care Enablement, offset by the expected decline in profit-neutral Value-Based Care * Operating income(2) decreased by 6%, due to regulatory and inflation headwinds * Reported operating income decreased by 19% and reported net income(3) decreased by 42%, mainly due to one-time costs related to the China strategy refinement * Earnings per share(2) (EPS) remained stable supported by the share buyback program * 348 U.S. clinics representing 16% of our U.S. dialysis machines converted to the 5008X CAREsystem™ with 1.3 million treatments(4) * FY 2026 outlook – revenue outlook broadly flat, operating income outlook narrowed to between flat and a negative mid-single digit percent growth rate BAD HOMBURG, Germany, Nov. 3, 2026 /PRNewswire/ -- "Three weeks into my role as CEO, I am energized by the opportunities ahead. As a global leader in kidney care, Fresenius Medical Care combines exceptional capabilities with unparalleled reach. Following the structural changes of recent years, many parts of our business are still at an early stage of development. This creates a compelling opportunity to deliver transformational improvements in performance, not simply the incremental gains typically associated with more mature businesses. We are muted in our assessment of performance and endeavor to improve the current trajectory over time," said Shervin J. Korangy, new Chief Executive Officer and Chair of the Management Board of Fresenius Medical Care. "With the FME25+ transformation, the company has built a solid foundation to continue to profitably grow and create value for all stakeholders. My focus will be on identifying opportunities to accelerate innovation, expand access to care, improve outcomes and drive long-term profitable growth."
Get started
Create a free account to read the full story.